Streetbeat News

Analyst Ratings

WNS

Analyst ratings for WNS (Hldgs) (NYSE:WNS) show mixed sentiments with a total of 3 bullish and 1 somewhat bullish ratings over the last quarter. The 12-month price targets have an average of $73.5, with a high of $80.00 and a low of $65.00, marking a decline from the previous average of $85.33. Citigroup and Barrington Research have adjusted their price targets and ratings, reflecting changes in market dynamics and company performance. WNS's financial indicators such as market capitalization, revenue growth, net margin, ROE, ROA, and debt management are also highlighted, with the company outperforming industry benchmarks in several areas.

Portfolio Pulse from Benzinga Insights

January 17, 2024 | 9:00 pm

EOLS

Evolus Inc (NASDAQ:EOLS) reported Q4 2023 revenue of $61 million, a 40% Y/Y increase, surpassing consensus estimates. Full-year revenue was $202 million, exceeding guidance and consensus. For FY 2024, Evolus forecasts revenues of $255-$265 million, with positive non-GAAP operating income expected in 2025. The company plans to submit FDA applications for Evolysse products in mid-2024 and anticipates European approvals for Estyme products in 2H 2024. Analysts from Needham, HC Wainwright, Cantor Fitzgerald, and Stifel maintain positive outlooks with Buy ratings and price targets ranging from $22 to $27. EOLS shares rose 21.24% to $12.50.

Portfolio Pulse from Vandana Singh

January 17, 2024 | 8:55 pm

MSCI

MSCI has publicly refuted the claims made in a report by short-seller Spruce Point, stating that the report contains misleading, incomplete, and false information. The firm's response comes after Spruce Point released a report that likely contains negative allegations about MSCI's business practices or financial health.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 8:50 pm

RKLB

KeyBanc analyst Michael Leshock initiated coverage on Rocket Lab USA Inc (NASDAQ:RKLB) with an Overweight rating and a price target of $8, citing a proven business model and a viable path to profitability within 1-3 years. The demand for launch services and satellite manufacturing is growing, and RKLB is well-positioned to meet this demand, supported by increasing government budgets for space applications. Leshock highlighted RKLB's track record with Electron and progress on Neutron, which is on schedule for a late 2024 launch. He also pointed out RKLB's attractive valuation and potential for significant upside if long-term initiatives are successful. Leshock's Q4 revenue and EPS projections are in line with consensus estimates. RKLB shares were down slightly at $4.92.

Portfolio Pulse from Anusuya Lahiri

January 17, 2024 | 8:42 pm

BURL

Piper Sandler analyst Edward Yruma upgraded Burlington Stores, Inc (NYSE:BURL) to Overweight from Neutral and raised the price target to $240 from $155. Yruma is confident in the company's potential for a 300+ basis points margin expansion and continued market share gains. He cites a favorable environment for off-price retailers due to conservative inventory buys by department stores. Yruma believes BURL's improved store experience and value offerings will drive market share growth, and the company's five-year guidance of 3-4% comparable store growth is achievable. After operational and cultural changes in 2022/2023, BURL is expected to refocus on long-term growth, aiming to return to 2018/2019 margin levels. FY23 revenue is projected at $9.571 billion, with FY24 revenue at $10.431 billion. BURL shares rose 1.58% to $196.42.

Portfolio Pulse from Nabaparna Bhattacharya

January 17, 2024 | 8:38 pm

DASH

Mizuho Securities analyst James Lee raised the price target for DoorDash Inc (NASDAQ:DASH) from $120 to $140, maintaining a Buy rating and Top Pick status. Lee anticipates resilient consumer spending in 2024, supporting growth in advertising, e-commerce, and gig economy services. Despite potential headwinds from consumer softness, Lee projects a 20% EBITDA growth for DASH in FY24, driven by gains in food and grocery delivery and potential growth from grocery advertising. DASH shares were trading down by 1.73% at $102.22.

Portfolio Pulse from Lekha Gupta

January 17, 2024 | 8:32 pm

A

QGEN

TWST

Goldman Sachs has upgraded Twist Bioscience Corp (TWST) from Neutral to Buy, anticipating that the launch of Express Genes in 2024 will address gross margin issues in their SynBio division and allow TWST to penetrate the larger biopharma market. The new product will enable faster gene delivery, which is expected to enhance revenue and profit margins. The market has a positive view of TWST's next-generation sequencing Tools business, but there are concerns about the SynBio division's gross margins. The biotech sector has seen a decrease in venture capital funding due to high interest rates and inflated valuations, but there are signs of a recovery, which could benefit TWST.

Portfolio Pulse from Vandana Singh

January 17, 2024 | 8:21 pm

INSE

Macquarie analyst Chad Beynon has downgraded Inspired Entertainment (NASDAQ:INSE) from Outperform to Neutral and reduced the price target from $16 to $10.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 8:19 pm

CNTY

Macquarie analyst Chad Beynon has downgraded Century Casinos (NASDAQ:CNTY) from Outperform to Neutral and reduced the price target from $8 to $5.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 8:17 pm

FLL

Macquarie analyst Chad Beynon downgraded Full House Resorts (NASDAQ:FLL) from Outperform to Neutral and reduced the price target from $8 to $6.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 8:16 pm